FDA Puts X-Ray Gadget in Safety Timeout Category
Published Date: 6/2/2025
Rule
Summary
The FDA is officially putting the radiological acquisition and/or optimization guidance system into a special safety category called Class II. This means the device will have clear rules to keep it safe and effective, helping patients get better tech faster. If you make or use these devices, expect smoother approvals and more innovation coming your way soon!
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Class II: Clear Rules for Makers
The FDA is classifying the radiological acquisition and/or optimization guidance system into Class II (special controls). This puts specific special controls into the device's codified classification and is intended to reduce regulatory burdens, which should make approvals smoother for companies that make these devices.
Faster Access to Safe Radiology Tech
The FDA determined that Class II (special controls) for this device type will provide a reasonable assurance of safety and effectiveness. The Agency also states this classification is expected to enhance patients' access to beneficial innovative devices by reducing regulatory burdens, which may help patients get updated radiology technology sooner.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20730, Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications; Correction
The FDA fixed a previous announcement about pulling approval for 16 generic drug applications. Three drugs from Navinta LLC—ribavirin solution, fosaprepitant powder, and nicardipine capsules—won't lose approval because Navinta asked to keep them active. This means those three drugs stay on the market, while the other 13 still had their approvals withdrawn as planned back in July 2026.
Previous / Next Documents
Previous: 2025-09777, Special Local Regulations; Marine Events Within the Fifth Coast Guard District-Cape May, NJ
On June 22, 2025, the Coast Guard will set special rules for the Around the Island Paddle event near Cape May, NJ to keep everyone safe on the water. Boat operators in the area must follow instructions from Coast Guard patrols, and anyone not part of the event needs permission to enter. This means some waterway access will be limited for a short time, but it’s all about making sure the event goes smoothly and safely.
Next: 2025-09856, Revocation of Class D and Class E4 Airspace; Establishment of Class E2 Airspace; Amendment of Class E5 Airspace, Aberdeen, MD
Phillips Army Airfield in Aberdeen, MD is changing its airspace rules because its control tower closed. They’re removing some old airspace zones and creating a new one to keep flights safe, especially for pilots flying by instruments. These updates also adjust nearby airspace after a navigation beacon was turned off, with no extra costs or delays expected.